Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The 56 Point TA; Charts With an Attitude -- Ignore unavailable to you. Want to Upgrade?

To: Doug R who wrote (12605)	2/22/1998 6:54:00 PM
From: Doug R	Read Replies (1) \| Respond to of 79268

The technicals on AIPN suggest a move to over 3 if volume comes in. It should be watched very closely at the open. The 2 day RSI is up against supply/demand resistance and a breakout on it would lead to a pop. If the resistance proves to be too much, any early move would be halted after one or 2 upticks. All other technicals are supportive of a move. Volume will be very important. If I didn't want to remind myself to remain conservative, I would say it will go. Doug R

To: Doug R who wrote (12605)	2/22/1998 7:44:00 PM
From: John McCarthy	Read Replies (1) \| Respond to of 79268

Doug - Excuse the intrusion. Was lurking. Post #4415 on Lizard King will summarize BIOX for you - from a fundamental side. Its my post. Or, you can see my post #175 on BIOX for a projected 98 P&L. If BIOX doesn't do $.18 this qtr. - the stock will fall. I'm long several 000 and have owned 2+ years. Regards, John McCarthy

To: Doug R who wrote (12605)	2/22/1998 10:17:00 PM
From: Doug R	Read Replies (1) \| Respond to of 79268

AMTR looks to have finally run into a bout of profit taking. I've been watching it run waiting for it to pull back and this week will probably tell if it is ready to continue back up. I would expect it to have at least one day this week with a large % move up. Doug R Ps; if anyone wants to jump in here and request one from the list or any other, I'll be back in 1/2 hr. I need to get to a couple of Keldog's requests too.

To: Doug R who wrote (12605)	2/23/1998 8:30:00 PM
From: Instock	Read Replies (2) \| Respond to of 79268

Doug: < OSIP > A stock from your List you posted Sunday. The Crunching Numbers, Insider Trades, and stuff... Insider Trades: OSIP WE CAN'T FIND A REPORT TO MATCH YOUR REQUEST. INSIDER TRANSACTIONS OF FEWER THAN 100 SHARES ARE NOT INCLUDED. ENTER A STOCK SYMBOL, OR TYPE /C TO SEARCH FOR A REPORT BY COMPANY NAME. * I guess this means there are no insiders buying or Selling.* EPS 2/14/98 Page 1 of 1 OSI PHARMACEUTICALS INC. Fiscal year ends 9/98 Earnings per share estimates --Mean $ -0.45 --High $ -0.45 --Low $ -0.45 P/E Ratio -14.17 (Estimated) Number of analysts 2 Past EPS estimates (Mean) -- Month ago -0.46 --13 Weeks ago -0.46 --26 Weeks ago -0.49 ************* Looks like company picked up a new analysts. An Extra Buy Rating this month * EPS 2/14/98 Page 1 of 3 OSI PHARMACEUTICALS INC. Analyst's ratings 2/14/98 Month ago Strong buy 1 1 Buy 2 1 Neutral 0 0 Sell 0 0 Strong sell 0 0 Total analysts 3 2 following company ****************** PROFESSIONAL INVESTOR REPORT 02/20 DOW JONES PIR PROFILE OSI Pharm (Q: OSIP) ESTIMATES UPDATED 2/12 Biopharm co. Uses Close 6 9/16 Consensus Rec. BUY proprietary tech to R&D 52-Week High 11 7/8 3 Analysts 1.7 treatments for cancer, 52-Week Low 4 1/4 1Q EPS Est None cardiovascular, other Dividend Yield None diseases releated to cell Industry Avg 1.36% 4Q Oper EPS (0.15) growth abnormalities. 8/97 1998 EPS Est (0.45) with Pfizer's (PFE), co 3 Analysts began phase I trials for Beta vs DJEI 2.44 1997 Oper EPS (0.44) CP-358,774 for cancer. 5-Yr EPS Growth n.a. Formerly Oncogene Sci. 1Q Rev $4.19M +80.9% Industry Avg 17.8% TTM $16.65M +70.6% P/E Ratio ... 1Q Ern ($2.47M) ... Industry Avg 28.85 TTM ($9.36M) ... Projected P/E None HQ Uniondale, NY 1-Yr Tot Rtrn (12.49%) IR Phone 516-222-0023 Industry Avg 51.97% (Updated 2/19 Sources: First Call, Market Guide For Help, use N/HLP) (END) Dow Jones Newswires 02-20-98 08:39 PM EST *******************************************************8 Financial Profile Data current through 02/20/1998 Osi Pharmaceuticals Inc 106 Charles Lindbergh Blvd Uniondale, NY 11553-3649 Telephone: (516) 222-0023 Fax: (516) 222-0114 Dow Jones Industry Group: Biotechnology Business Description: Drug discovery company applying proprietary, broadly enabling technologies to rapidly and cost-effectively discover and develop novel small molecule compounds for the treatment of major human diseases. Primary SIC: 2835 SIC Codes: 8099 8731 Stock Symbol: OSIP Exchange: NASDAQ CEO: Gary E. Frashier Employees: 156 Auditors: KPMG Peat Marwick LLP Latest Report: Unqualified Share Data Latest Reported Shares Outstanding 21,367,000 Latest Shares Outstanding Date 02/17/1998 Latest Balance Sheet Shares Outstanding 21,367,000 Short Interest Shares 53,410 Short Interest Ratio 0.8 Days Short Interest Ratio Date 01/08/1998 Net Insider Transactions 0 Net Insider Transactions Date 12/31/1997 Shares Held by Institutions 6,809,000 Number of Institutions Holding 52 % of Shares Held by Institutions 30.7 Institutional Holding Date 01/31/1998 Market Value($ Mil) 147 Market Value as % Revenues 993 Dividend Information Last Ex-Dividend Date NA Indicated Dividend Rate 0.00 Dividend Yield 0.0% Dividend Code Payout Ratio Last Fiscal Year NC 5-Year Average Payout NC 5-Year Dividend Yield 0.0% Stock Price ($) And Volume Most Recent Close Price 6.88 Most Recent Close Price Date 02/20/1998 Close Price 4 Weeks Ago 7.50 Close Price 13 Weeks Ago 7.38 Close Price 26 Weeks Ago 8.75 Close Price 52 Weeks Ago 7.13 Price Change Last Month 9.0% Price Change Last 10 Days 11.1% Price Change Last 26 Weeks -21.4% Price Change Last 52 Weeks -3.5% Price Change YTD 1.9% Price Change vs Market Last Trading Week 106% Price Change vs Market Last 4 Weeks 85% Price Change vs Market Last 13 Weeks 87% Price Change vs Market Last 26 Weeks 70% Price Change vs Market Last 52 Weeks 75% Price Change vs Market YTD 96% 4-Week High Price 7.44 4-Week Low Price 5.75 13-Week High Price 8.31 13-Week Low Price 5.75 26-Week High Price 11.88 26-Week Low Price 5.75 52-Week High Price 11.88 52-Week Low Price 4.25 YTD High Price 8.31 YTD Low Price 5.75 5-Day Moving Avg Price 6.59 10-Day Moving Avg Price 6.40 10-Week Moving Avg Price 6.83 30-Week Moving Avg Price 8.40 200-Day Moving Avg Price 7.82 Beta, Up Market 3.91 Beta, Down Market 4.46 Shares Traded This Week 157,100 Volume as % of Shares Outstanding 0.74% Avg Daily Volume Last 2 Weeks 112,200 Avg Daily Volume Last 4 Weeks 122,000 Avg Daily Volume Last 13 Weeks 95,500 Avg Daily Volume Last 26 Weeks 116,600 Avg Daily Volume Last 52 Weeks 103,000 Avg Daily Volume YTD 97,300 On-Balance Volume Index Last 4 Weeks 198% Liquidity Ratio 15,830 P/E Ratio NE 5-Year High P/E NC 5-Year Low P/E NC Selected Balance Sheet Items ($ Mil) Fiscal Year End 09/30/1997 09/30/1996 09/30/1995 09/30/1994 Cash & Equivalent 8.6 13.4 17.9 0.3 Receivables 1.9 2.8 1.3 20.9 Inventories 0.0 0.0 0.0 1.7 Current Assets 34.5 51.0 29.1 24.2 Gr Fixed Assets 18.2 15.4 12.6 12.4 Accum Depr & Depl 10.4 8.9 6.9 5.8 Net Fixed Assets 7.8 6.5 5.7 6.6 Total Assets 59.6 73.5 44.1 42.0 Accounts Payable 4.2 3.7 2.8 2.5 Short-Term Debt 0.7 0.0 0.0 0.0 Curr Liabilities 4.9 3.8 3.0 3.0 Long-Term Debt 0.2 0.1 0.2 0.2 Total Liabilities 6.7 5.2 3.6 3.4 Preferred Equity 0.0 0.0 0.0 0.0 Common Equity 52.9 68.3 40.5 38.7 Retained Earnings -45.7 -36.1 -26.1 -21.9 Total Equity 52.9 68.3 40.5 38.7 Liabs & Equity 59.6 73.5 44.1 42.1 Working Capital 29.6 47.2 26.1 21.2 Selected Income Statement Items ($ Mil) Fiscal Year End 09/30/1997 09/30/1996 09/30/1995 09/30/1994 Revenues/Sales 14.8 9.7 15.9 16.3 Cost of Sales -2.0 -2.1 0.2 0.3 Gr Oper Profit 16.8 11.8 15.7 16.0 S,G & A Expenses 24.3 20.2 20.7 19.6 Deprec & Amort 4.1 3.7 2.7 2.9 Interest Expense 0.0 0.0 0.0 0.0 Pretax Income -9.6 -9.9 -4.3 -5.7 Income Taxes 0.0 0.0 0.0 0.0 Minority Interest 0.0 0.0 0.0 0.0 Net Inc Cont Ops -9.6 -9.9 -4.3 -5.7 Net Inc Disc Ops 0.0 0.0 0.0 0.0 Net Inc Tot Ops -9.6 -9.9 -4.3 -5.7 Extra Inc (Loss) 0.0 0.0 0.0 0.0 Net Income -9.6 -9.9 -4.3 -5.7 EPS Cont Ops -0.44 -0.50 -0.25 -0.35 EPS Disc Ops 0.00 0.00 0.00 0.00 EPS Total Ops -0.44 -0.50 -0.25 -0.35 EPS Extra Inc 0.00 0.00 0.00 0.00 EPS fr Net Income -0.44 -0.50 -0.25 -0.35 Domestic Sales NA NA NA NA Foreign Sales NA NA NA NA Income Statement YTD (last annual value if no qtrly aval for cur yr) Revenues/Sales($ Mil) 14.8 Inc fr Total Ops($ Mil) -9.6 EPS fr Total Ops($) -0.44 Dividends per Share($) 0.00 Selected Cash Flow Statement Items ($ Mil) Fiscal Year End 09/30/1997 09/30/1996 09/30/1995 09/30/1994 Net Income -9.6 -9.9 -4.3 -5.7 Deprec & Amort 4.1 3.7 2.7 2.9 Chg Receivables 1.0 -0.7 1.9 0.2 Chg Payables 0.5 0.4 -0.6 0.2 Net Cash fr Ops -3.4 -6.1 -3.0 -2.2 Net Cash fr Inv 7.0 -30.4 15.1 1.6 Net Cash fr Fin -8.3 32.0 5.5 0.0 Eff Exch Rate Chg 0.0 0.0 0.0 0.0 Net Chg Cash & Eq -4.8 -4.5 17.6 -0.5 Cash Begin Period 13.4 17.9 0.3 0.8 Key Financial Ratios Fiscal Year End 09/30/1997 09/30/1996 09/30/1995 09/30/1994 Book Value P/S 2.48 3.11 2.32 2.37 Price/Book Val(%) 439 285 232 137 Debt/Equity(%) 0 0 0 1 LT Debt % Inv Cap 0.4 0.1 0.5 0.5 LT Debt % Tot Dbt 3.0 1.9 5.6 5.9 Dbt % Tot Assets 11.2 7.1 8.2 8.1 Quick Ratio 2.1 4.3 6.4 7.1 Current Ratio 7.0 13.4 9.7 8.1 Revenue/Assets(%) 20 10 40 40 Price/Revenue(%) 1,576 2,017 591 325 Cash % Revenue 58.1 138.1 112.6 1.8 Pre-Tax Mgn(%) -64.9 NC -27.0 -35.0 Post-Tax Mgn(%) -64.9 NC -27.0 -35.0 Eff Tax Rate(%) 0.0 0.0 0.0 0.0 Asset Turnover 0.2 0.2 0.4 0.4 Receivable Turn 6.3 4.7 1.4 0.7 Inventory Turn NC NC 0.2 0.2 Ret on Equity(%) NE NE NE NE Ret Invest Cap(%) -18.1 -14.5 -10.6 -14.7 Ret on Assets(%) -16.1 -13.5 -9.8 -13.6 Growth Rates 5-Yr Annual EPS Growth NC 5-Yr Annual Div Growth NC 5-Yr Annual Revenue Growth -1.15% % Change EPS YTD vs Last YTD NE $ Change in EPS this YTD vs Last YTD 0.00